[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362592-105":59,"doc-detail-362592-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","arid1a-deficiency-activates-osm-stat3-axis-in-endometrial-cancer-creating-vulnerability-to-jakstat3-inhibition","ARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition","","ARID1A loss, a common event in endometrial cancer and a key SWI/SNF chromatin remodeling component, is explored as a therapeutic vulnerability. A synthetic lethal drug screen identifies the JAK/STAT3 pathway as selectively targetable in ARID1A-deficient endometrial cancer. JAK/STAT3 inhibition restrains growth in vitro and in a mouse xenograft model. Mechanistically, ARID1A deficiency activates JAK/STAT3 by promoting Oncostatin M transcription, driving PLK1 elevation, mitotic abnormalities, and death, while OSM inversely tracks ARID1A in patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/arid1a-deficiency-activates-osm-stat3-axis-in-endometrial-cancer-creating-vulnerability-to-jakstat3-inhibition/362592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/arid1a-deficiency-activates-osm-stat3-axis-in-endometrial-cancer-creating-vulnerability-to-jakstat3-inhibition/362592.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic vulnerability is linked to ARID1A deficiency in endometrial cancer?","Question",{"text":112,"@type":113},"The study identifies the JAK/STAT3 pathway as a therapeutic vulnerability specifically in ARID1A-deficient endometrial cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ARID1A deficiency activate JAK/STAT3 signaling?",{"text":117,"@type":113},"ARID1A deficiency promotes transcription of the pleiotropic cytokine Oncostatin M (OSM), which then stimulates JAK/STAT3 signaling.",{"name":119,"@type":110,"acceptedAnswer":120},"What downstream effects lead to sensitivity to JAK/STAT3 and PLK1 inhibitors?",{"text":121,"@type":113},"OSM-driven JAK/STAT3 activation increases PLK1 levels, causing mitotic abnormalities; ARID1A-deficient cells become highly vulnerable to JAK/STAT3 and PLK1 inhibition for mitotic arrest and death.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362592,1790180094,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2026; 22(5): 2638-2653. doi: 10.7150/ijbs.129142  \nResearch Paper  \nARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition  \nLi-Jie Chen1, Changxiang Shi2, Eun Ju Yang1, Guowen Ren1,3, Shishi Tao1,3, Yue Pu1, Xiumei Zhang1, Xin Shen1, Changjie Wu4, Joong Sup Shim1,5􀀍  \n1. Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.  \n2. Nanjing Key Laboratory of Female Fertility Preservation and Restoration, Nanjing Women and Children's Healthcare Institute, Women's Hospital of Nanjing Medical University (Nanjing Women and Children's Healthcare Hospital), Nanjing, 210004, China.  \n3. Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, Guangdong, 518055, China.  \n4. Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.  \n5. MOE Frontiers Science Centre for Precision Oncology, University of Macau, Taipa, Macau SAR, China.  \n􀀍 Corresponding author: Joong Sup Shim, [Ph.D. Email: jsshim@um.edu.mo](Ph.D. Email: jsshim@um.edu.mo); Tel: +853-8822-4990.  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.11.28; Accepted: 2026.01.18; Published: 2026.02.11  \nAbstract  \nARID1A, a key component of the SWI/SNF chromatin remodeling complex, is a tumor suppressor frequently inactivated in many cancer types, including endometrial cancer. Exploiting ARID1A deficiency has emerged as a therapeutic strategy in these types of cancer. We here employed a synthetic lethal drug screen for ARID1A and found that JAK/STAT3 pathway is a therapeutic vulnerability in ARID1A-deficient endometrial cancer. Inhibition of JAK/STAT3 selectively inhibited the growth of ARID1A deficient endometria cancer cells in vitro and in a mouse xenograft tumor model. Mechanistically, ARID1A deficiency activates JAK/STAT3 signaling through promoting the transcription of the pleiotropic cytokine Oncostatin M (OSM). Autocrine activation of JAK/STAT3 signal by OSM in ARID1A-deficient endometrial cancer cells promotes PLK1 levels, inducing mitotic abnormality. These cells are highly vulnerable to JAK/STAT3 and PLK1 inhibitors for mitotic arrest and death. ARID1A and OSM protein levels are inverse correlated in patients with endometrial cancer, where elevated OSM levels are associated with poor patient survival. Our study indicates that OSM-STAT3-PLK1 axis inhibition presentsa new therapeutic approach for endometrial cancer with ARID1A loss.  \nKeywords: endometrial cancer, synthetic lethality, ARID1A, OSM/STAT3/PLK1 axis  \nIntroduction  \nEndometrial cancer (EC) is the sixth most common carcinoma in women [1], with its incidence rate increasing over the past decades [2] . The standard surgical treatment for EC is a total hysterectomy with bilateral salpingo-oophorectomy. However, this surgical approach results in loss of fertility and is only suitable for early-stage EC [3] . For advanced cases, pharmacological therapy becomes essential. The current first-line drug treatment includes chemotherapy agents such as carboplatin and paclitaxel, which are associated with severe side effects [4] . Although mTOR inhibitors and immune  \ncheckpoint inhibitors have been developed for EC, they exhibit limited antitumor activity or significant treatment-related toxicity [5, 6] . Immune checkpoint inhibitors like pembrolizumab and dostarlimab, approved by the US Food and Drug Administration (FDA) for mismatch repair-deficient advanced or relapsed endometrial cancer, show better efficacy but still result in grade 3-4 treatment-related toxicit","cbCaifVi46PNTRHS","https://ap.wps.com/l/cbCaifVi46PNTRHS","pdf",9778254,16,"English","# Abstract\n# Introduction\n# Materials and Methods","[{\"question\":\"What therapeutic vulnerability is linked to ARID1A deficiency in endometrial cancer?\",\"answer\":\"The study identifies the JAK/STAT3 pathway as a therapeutic vulnerability specifically in ARID1A-deficient endometrial cancer.\"},{\"question\":\"How does ARID1A deficiency activate JAK/STAT3 signaling?\",\"answer\":\"ARID1A deficiency promotes transcription of the pleiotropic cytokine Oncostatin M (OSM), which then stimulates JAK/STAT3 signaling.\"},{\"question\":\"What downstream effects lead to sensitivity to JAK/STAT3 and PLK1 inhibitors?\",\"answer\":\"OSM-driven JAK/STAT3 activation increases PLK1 levels, causing mitotic abnormalities; ARID1A-deficient cells become highly vulnerable to JAK/STAT3 and PLK1 inhibition for mitotic arrest and death.\"}]","ARID1A deficiency activates OSM-STAT3 axis in endometrial cancer, creating vulnerability to JAK/STAT3 inhibition | PDF",1790148486,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed95538ba7a18e67c1d18e65447c5ada.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1e1b46bea3f18987f35e93c929d9161.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fff0020346262180d5a37aca9970b219.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5426e8138254b60a40bd49626c7e7898.webp",980,1268]